Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases. Cambridge Brain Mets Trial 1 (CamBMT1): A proof of principle study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback